Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

NCT03412799 is registered in ClinicalTrials.gov with Panbela Therapeutics, Inc. as lead sponsor.

NCT NCT03412799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03412799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Panbela Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 4, 2018
Completion date
February 28, 2022
Enrollment
50 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer metastatic, pancreatic cancer stage iv, stage iv pancreatic cancer